
New research found that the late arterial phase, which accounts for approximately 40 percent of CT radiation dosing in cases involving acute abdominal pain, offered no exclusive findings that had an impact on clinical care.
Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has
Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has licensed the agent from its developer, ImaRx Pharmaceutical of Tucson.




